Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary POAI ‘s Helomics Division Announces Progress on Milestones for its AI-Driven Model of Ovarian Cancer
Helomics Researchers Complete Key Sequencing Milestones and Focus on AI-Driven Model Building MINNEAPOLIS , Feb. 24, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug
View HTML
Toggle Summary Predictive Oncology Announces Closing of $17.6 Million Private Placement Priced At-the-Market
MINNEAPOLIS , Feb. 23, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the closing of its previously
View HTML
Toggle Summary Predictive Oncology Announces $17.6 Million Private Placement Priced At-the-Market
MINNEAPOLIS , Feb. 18, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today that it has entered into securities
View HTML
Toggle Summary Two Top Researchers find Breakthrough Discoveries using Predictive Oncology’s Wholly Owned Subsidiary, TumorGenesis’s Technology
MINNEAPOLIS , Feb. 17, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that the products of its wholly owned subsidiary, TumorGenesis, aided
View HTML
Toggle Summary Predictive Oncology Announces Closing of $7.4 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
MINNEAPOLIS , Feb. 16, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the closing of its previously
View HTML
Toggle Summary Predictive Oncology Announces $7.4 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
MINNEAPOLIS , Feb. 10, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it has entered into
View HTML
Toggle Summary Predictive Oncology’s Wholly Owned Subsidiary Helomics announces the start of its drug repurposing project using its ground-breaking PeDAL™ platform for ovarian cancer
MINNEAPOLIS , Feb. 08, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that it will start an in-house drug repurposing project, focused on ovarian
View HTML
Toggle Summary Predictive Oncology Has Regained Compliance with Nasdaq’s Minimum Bid Price Requirement
MINNEAPOLIS , Feb. 02, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that based on a notification
View HTML
Toggle Summary Litchfield Hills Research Rates Predictive Oncology a Buy on Recent Analyst Report
MINNEAPOLIS , Feb. 02, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that equity research firm, Litchfield Hills Research LLC, released its
View HTML
Toggle Summary Soluble Biotech, a Wholly Owned Subsidiary of Predictive Oncology, Inked Contract with Large Pharmaceutical Company
MINNEAPOLIS , Jan. 28, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that its wholly owned subsidiary Soluble Biotech, Inc.
View HTML